The knock-down of CLPTM1L with siRNA or targeting with an anti-CLPTM1L antibody increased the sensitivity of CLPTM1L overexpressing cancer cells to killing through genotoxic stress inducing agents [17,30]. The gene discussed is CLPTM1L; the disease is cancer.